Dose-ranging Study to Assess the Efficacy and Safety of Ciclesonide HFA Nasal Aerosol in Adult and Adolescent Patients 12 Years and Older With Seasonal Allergic Rhinitis (SAR) (BY9010/M1-602)

NCT00807053 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic, Seasonal

Interventions

DRUG: Ciclesonide HFA
DRUG: Ciclesonide HFA
DRUG: Ciclesonide HFA
DRUG: Placebo

Sponsor

AstraZeneca